DKSH Malaysia teams up with Pfizer to boost access to anti-infective therapies
Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments
Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Changhua site meets international regulatory standards for global medical applications
Amaran Biotech boasts Taiwan’s first fully automated robotic aseptic filling line, offering high-quality and low-waste filling solutions for high-value pharmaceuticals
Subscribe To Our Newsletter & Stay Updated